Kyverna Therapeutics shareholders elect Ian Clark and Christi Shaw as Class II directors, ratify BDO USA auditor

Kyverna Therapeutics, Inc.

73% of outstanding shares (43.99M of 60.53M) represented at May 27, 2026 annual meeting, forming quorum.
Ian Clark elected as Class II director: 31,505,902 for, 3,255,231 withheld, 9,225,874 broker non-votes.
Christi Shaw elected as Class II director: 34,528,865 for, 232,268 withheld, 9,225,874 broker non-votes.
BDO USA ratified as independent auditor for FY 2026: 43,830,300 for, 80,223 against, 76,484 abstain.

item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Kyverna Therapeutics, Inc. shareholders approved Election of two Class II directors at the 2026-05-27 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-27

Exact text from the filing

Director Nominee Votes For Votes Withheld Broker Non-Votes Ian Clark 31,505,902 3,255,231 9,225,874 Christi Shaw 34,528,865 232,268 9,225,874

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Kyverna Therapeutics, Inc. shareholders approved Ratification of appointment of BDO USA, P.C. as independent registered public accounting firm at the 2026-05-27 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-27

Exact text from the filing

Votes For Votes Against Abstentions 43,830,300 80,223 76,484

View on SEC.gov

Browse all shareholder votes →

Kyverna Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-253604

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.